Chronic Pain News and Research

RSS

Childhood bad behaviour linked to chronic widespread pain in adult life

Bad behaviour in childhood is associated with long-term, chronic widespread pain in adult life, according to the findings of a study following nearly 20,000 people from birth in 1958 to the present day.

10 Mar 2010

International Merchant Advisors creates IMAI Wellness Centers in Colorado

International Merchant Advisors, Inc. www.imaiinc.com announced today that the company has created a new subsidiary in Colorado, IMAI Wellness Centers, Inc., to pursue the development of the company's new Wellness Centers and Medical Marijuana clinics for chronic pain relief.

9 Mar 2010

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

Bristol-Myers Squibb Company and Allergan, Inc. today announced a global agreement for the development and commercialization of AGN-209323, a Phase II-ready, orally administered small molecule in clinical development for neuropathic pain.

3 Mar 2010

FDA approves CombinatoRx's NDA for Exalgo extended-release tablets

CombinatoRx, Incorporated today announced that the U.S. Food and Drug Administration has approved the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

2 Mar 2010

IMAI reaches agreement in principal to acquire Organic Science for $15M

International Merchant Advisors, Inc. www.imaiinc.com announced today that the company has reached an agreement in principal to acquire its first operating business in the clinical medical marijuana space. IMAI has agreed to acquire Organic Science, Inc. for $15 million in the restricted common stock of IMAI.

2 Mar 2010

TMI's Glider balloon catheter for PTA of lesions in peripheral vasculature receives FDA marketing clearance

TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for its newest product, the Glider™ balloon catheter, for percutaneous transluminal angioplasty (PTA) of lesions in the peripheral vasculature including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries.

25 Feb 2010

Study: People can reduce their sensitivity to pain by thickening their brain

People can reduce their sensitivity to pain by thickening their brain, according to a new study published in a special issue of the American Psychological Association journal, Emotion. Researchers from the Universit- de Montr-al made their discovery by comparing the grey matter thickness of Zen meditators and non-meditators.

25 Feb 2010

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

MicroTransponder, Inc., a privately-held medical device company, has just announced a $7 Million Series B round of funding. MicroTransponder is developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications.

25 Feb 2010

Aetna selects Millennium Laboratories as national pain management services provider

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, announced today a national agreement with Aetna, one of the nation’s leading diversified health care benefits companies that serves approximately 36.3 million people. Under the terms of the three-year ancillary services agreement which went into effect February 1, 2010, Millennium Laboratories’ will assist Aetna participating physicians nationwide with state-of-the-art therapeutic drug monitoring services and tools.

23 Feb 2010

International Merchant Advisors signs LOI to purchase minority interest in Assured Pharmacy

International Merchant Advisors, Inc. www.imaiinc.com announced today that the company has signed a letter of intent to purchase a minority interest in Assured Pharmacy, Inc. www.assuredpharmacyinc.com, a retail pharmaceutical operation that is focused on selling prescription medications in the chronic pain management medical sector.

16 Feb 2010

IMAI formally offered to purchase equity position in pharmaceutical operation

International Merchant Advisors, Inc. announced today that the company has formally offered to purchase an equity position in a pharmaceutical operation that is focused on selling in the chronic pain management medical sector.

15 Feb 2010

Sales of Cobroxin exceeds XenaCare Holdings' projections for first 45 days of 2010

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, announced today that it has begun distributing and selling Cobroxin through mass food and drug retail chains in the Northeast, Southeast, Middle Atlantic and Midwest regions.

12 Feb 2010

Cognitive behavioral therapy effective for insomnia and chronic pain

Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.

11 Feb 2010

Neurotoxin study may help find new therapies to block hyperactive ion channels

There are approximately 500 species of cone snails, each producing 50 - 200 different conotoxins. A similar number of peptide toxins are produced by snakes, spiders, sea anemones, scorpions and other venomous animals. The animals use the neurotoxins to paralyze their prey.

11 Feb 2010

Silver nanoparticles in higher-power, longer-life batteries for ICDs

Diamonds and gold may make some hearts flutter on Valentine's Day, but in a University at Buffalo laboratory, silver nanoparticles are being designed to do just the opposite.

11 Feb 2010

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

QRxPharma Limited announced today initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone.

11 Feb 2010

AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA

AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).

10 Feb 2010

Toronto Rehab scientists develop SoleSensor to help older people stay on their feet

In an aging society, falling is a growing problem. Just one bad fall can mark the start of a downward spiral in an older person's health and quality of life. The cost of treating falls also puts a heavy burden on the health care system. Toronto Rehab scientists have developed a simple footwear insole called SoleSensor(TM), which has proven to improve balance and prevent falls.

10 Feb 2010

Laser Spine Institute recognized as ‘Medical Partner of the Year’

This year, Gridiron Greats recognized LSI at the event as Medical Partner of the Year. LSI's medical director Dr. Michael Perry and CEO Bill Horne accepted the award.

10 Feb 2010

TI commences Phase IIa clinical trial for its lead molecule in CDH

Trigemina, Inc. (TI), a Mountain View based startup, has begun a Phase IIa clinical trial for its lead molecule in Chronic Daily Headache (CDH) in collaboration with Dr. Egilius Spierings at MedVadis Research Corporation located outside of Boston.

10 Feb 2010

Chronic Pain News and Research

Childhood bad behaviour linked to chronic widespread pain in adult life

International Merchant Advisors creates IMAI Wellness Centers in Colorado

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

FDA approves CombinatoRx's NDA for Exalgo extended-release tablets

IMAI reaches agreement in principal to acquire Organic Science for $15M

TMI's Glider balloon catheter for PTA of lesions in peripheral vasculature receives FDA marketing clearance

Study: People can reduce their sensitivity to pain by thickening their brain

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

Aetna selects Millennium Laboratories as national pain management services provider

International Merchant Advisors signs LOI to purchase minority interest in Assured Pharmacy

IMAI formally offered to purchase equity position in pharmaceutical operation

Sales of Cobroxin exceeds XenaCare Holdings' projections for first 45 days of 2010

Cognitive behavioral therapy effective for insomnia and chronic pain

Neurotoxin study may help find new therapies to block hyperactive ion channels

Silver nanoparticles in higher-power, longer-life batteries for ICDs

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA

Toronto Rehab scientists develop SoleSensor to help older people stay on their feet

Laser Spine Institute recognized as ‘Medical Partner of the Year’

TI commences Phase IIa clinical trial for its lead molecule in CDH

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News